Skip to content
2000
image of Risk of Autoimmune Rheumatic Diseases following COVID-19: A Systematic Review and Meta-Analysis

Abstract

Introduction

Multiple cases of autoimmune rheumatic diseases following COVID-19 have been reported in the literature. This study aims to systematically determine whether COVID-19 affects the incidence of autoimmune rheumatic diseases.

Methods

We searched MEDLINE (PubMed), Global Index Medicus, and Cochrane Library databases up to March 30, 2024, for studies evaluating the incidence of systemic autoimmune diseases following SARS-CoV-2 infection in adult populations.

Results

Eight cohort studies with 5,537,742 COVID-19 and 18,433,129 non-COVID-19 patients were included in our pooled analysis. The risk of developing mixed connective tissue disease and Behçet’s disease in COVID-19 patients was increased by 168% (RR: 2.68, 95% CI (1.14 to 6.34), I2=94%) and 101% (RR: 2.01, 95% CI (1.4 to 2.87), I2=6%), respectively, compared to uninfected subjects. A 45% increase in the risk of both rheumatoid arthritis (RR: 1.45, 95% CI (1.02 to 2.06), I2=99%) and psoriasis (RR: 1.45, 95% CI (1.10 to 1.92), I2=98%) after SARS-CoV-2 infection was noted. The risk of dermatopolymyositis was 40% higher (RR: 1.40, 95% CI (1.10 to 1.79), I2=68%) in the COVID-19 group. Non-significant increases in risk were observed in the pooled analysis for ankylosing spondylitis (RR: 1.39, 95% CI (0.94 to 2.05), I2=93%), systemic lupus erythematosus (RR: 1.21, 95% CI (0.70 to 2.07), I2=98%), systemic sclerosis (RR: 1.23, 95% CI (0.73 to 2.04), I2=89%), Sjögren’s syndrome (RR: 1.28, 95% CI (0.91 to 1.80), I2=95%), and polymyalgia rheumatica (RR: 1.45, 95% CI (0.94 to 2.25), I2=94%).

Discussion

Since the onset of COVID-19, several cases of new-onset autoimmune rheumatic diseases following SARS-CoV-2 infection have been reported. To the best of our knowledge, this is the first systematic review and meta-analysis assessing the impact of COVID-19 on the risk of developing autoimmune rheumatic diseases. Overall, COVID-19 increases the risk of autoimmune rheumatic diseases, especially during the first year after infection.

Conclusion

COVID-19 is associated with an increased risk of several autoimmune rheumatic diseases, including mixed connective tissue disease, Behçet’s disease, rheumatoid arthritis, psoriasis, and dermatopolymyositis. However, our results must be interpreted with caution due to high inter-study heterogeneity.

Registration

PROSPERO CRD42023480593

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/crr/10.2174/0115733971382167250921213314
2025-10-02
2025-11-03

  • From This Site

    /content/journals/crr/10.2174/0115733971382167250921213314
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Coronavirus disease (COVID-19) outbreak 2024. 2024 Available from: https://covid19.who.int/
  2. Dotan A. Muller S. Kanduc D. David P. Halpert G. Shoenfeld Y. The SARS-CoV-2 as an instrumental trigger of autoimmunity. Autoimmun. Rev. 2021 20 4 102792 10.1016/j.autrev.2021.102792 33610751
    [Google Scholar]
  3. Agmon-Levin N. Paz Z. Israeli E. Shoenfeld Y. Vaccines and autoimmunity. Nat. Rev. Rheumatol. 2009 5 11 648 652 10.1038/nrrheum.2009.196 19865091
    [Google Scholar]
  4. Guo M. Liu X. Chen X. Li Q. Insights into new-onset autoimmune diseases after COVID-19 vaccination. Autoimmun. Rev. 2023 22 7 103340 10.1016/j.autrev.2023.103340 37075917
    [Google Scholar]
  5. Saeedi N. Gohari N.S.F. Ghalibaf A.A.M. Dehghan A. Owlia M.B. COVID-19 infection: A possible induction factor for development of autoimmune diseases? Immunol. Res. 2023 71 4 547 553 10.1007/s12026‑023‑09371‑7 37316687
    [Google Scholar]
  6. Makris A. Barkas F. Sfikakis P.P. Lipoprotein(a), Interleukin-6 inhibitors, and atherosclerotic cardiovascular disease: Is there an association? Atheroscler Plus 2023 54 1 6 10.1016/j.athplu.2023.09.001 37720252
    [Google Scholar]
  7. Sweeney D.A. Lobo S.M. Póvoa P. Kalil A.C. Choosing immunomodulating therapies for the treatment of COVID-19: Recommendations based on placebo-controlled trial evidence. Clin. Microbiol. Infect. 2024 30 5 611 618 10.1016/j.cmi.2023.12.028 38182048
    [Google Scholar]
  8. Grainger R. Kim A.H.J. Conway R. Yazdany J. Robinson P.C. COVID-19 in people with rheumatic diseases: Risks, outcomes, treatment considerations. Nat. Rev. Rheumatol. 2022 18 4 191 204 10.1038/s41584‑022‑00755‑x 35217850
    [Google Scholar]
  9. Zacharias H. Dubey S. Koduri G. D’Cruz D. Rheumatological complications of Covid 19. Autoimmun. Rev. 2021 20 9 102883 10.1016/j.autrev.2021.102883 34237419
    [Google Scholar]
  10. Page M.J. McKenzie J.E. Bossuyt P.M. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 2021 372 71 n71 10.1136/bmj.n71 33782057
    [Google Scholar]
  11. Peterson J Welch V Losos M Tugwell P. The newcastle-ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2011 2 1 1 2 Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
  12. Guyatt G. Oxman A.D. Akl E.A. GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables. J. Clin. Epidemiol. 2011 64 4 383 394 10.1016/j.jclinepi.2010.04.026 21195583
    [Google Scholar]
  13. Chang R. Yen-Ting Chen T. Wang S.I. Hung Y.M. Chen H.Y. Wei C.C.J. Risk of autoimmune diseases in patients with COVID-19: A retrospective cohort study. EClinicalMedicine 2023 56 101783 10.1016/j.eclinm.2022.101783 36643619
    [Google Scholar]
  14. Hileman C.O. Malakooti S.K. Patil N. Singer N.G. McComsey G.A. New-onset autoimmune disease after COVID-19. Front. Immunol. 2024 15 1337406 10.3389/fimmu.2024.1337406 38390319
    [Google Scholar]
  15. Inokuchi S. Shimamoto K. Persistent risk of developing autoimmune diseases associated with covid-19. J. Clin. Rheumatol. 2024 30 2 65 72 10.1097/RHU.0000000000002054 38190730
    [Google Scholar]
  16. Kim M.S. Lee H. Lee S.W. Long-term autoimmune inflammatory rheumatic outcomes of covid-19. Ann. Intern. Med. 2024 177 3 291 302 10.7326/M23‑1831 38437702
    [Google Scholar]
  17. Lim S.H. Ju H.J. Han J.H. Autoimmune and autoinflammatory connective tissue disorders following covid-19. JAMA Netw. Open 2023 6 10 2336120 10.1001/jamanetworkopen.2023.36120 37801317
    [Google Scholar]
  18. Marín J.S. Mazenett-Granados E.A. Salazar-Uribe J.C. Increased incidence of rheumatoid arthritis after COVID-19. Autoimmun. Rev. 2023 22 10 103409 10.1016/j.autrev.2023.103409 37597602
    [Google Scholar]
  19. Peng K. Li X. Yang D. Risk of autoimmune diseases following COVID-19 and the potential protective effect from vaccination: A population-based cohort study. EClinicalMedicine 2023 63 102154 10.1016/j.eclinm.2023.102154 37637754
    [Google Scholar]
  20. Syed U. Subramanian A. Wraith D.C. Incidence of immune-mediated inflammatory diseases following COVID-19: A matched cohort study in UK primary care. BMC Med. 2023 21 1 363 10.1186/s12916‑023‑03049‑5 37735654
    [Google Scholar]
  21. Tesch F. Ehm F. Vivirito A. Incident autoimmune diseases in association with SARS-CoV-2 infection: A matched cohort study. Clin. Rheumatol. 2023 42 10 2905 2914 10.1007/s10067‑023‑06670‑0 37335408
    [Google Scholar]
  22. Hali F. Jabri H. Chiheb S. Hafiani Y. Nsiri A. A concomitant diagnosis of COVID‐19 infection and systemic lupus erythematosus complicated by a macrophage activation syndrome: A new case report. Int. J. Dermatol. 2021 60 8 1030 1031 10.1111/ijd.15592 33864388
    [Google Scholar]
  23. De Stefano L. Rossi S. Montecucco C. Bugatti S. Transient monoarthritis and psoriatic skin lesions following COVID-19. Ann. Rheum. Dis. 2023 82 4 86 10.1136/annrheumdis‑2020‑218520 32753423
    [Google Scholar]
  24. Schioppo T. Argolini L.M. Sciascia S. Clinical and peculiar immunological manifestations of SARS-CoV-2 infection in systemic lupus erythematosus patients. Rheumatology 2022 61 5 1928 1935 10.1093/rheumatology/keab611 34352079
    [Google Scholar]
  25. Golstein M.A. Fagnart O. Steinfeld S.D. Reactive arthritis after COVID-19 vaccination: 17 cases. Rheumatology 2023 62 11 3706 3709 10.1093/rheumatology/kead169 37084272
    [Google Scholar]
  26. Joo Y.B. Lim Y.H. Kim K.J. Park K.S. Park Y.J. Respiratory viral infections and the risk of rheumatoid arthritis. Arthritis Res. Ther. 2019 21 1 199 10.1186/s13075‑019‑1977‑9 31470887
    [Google Scholar]
  27. Gugliesi F. Pasquero S. Griffante G. Human cytomegalovirus and autoimmune diseases: Where are we? Viruses 2021 13 2 260 10.3390/v13020260 33567734
    [Google Scholar]
  28. Segal Y. Shoenfeld Y. Vaccine-induced autoimmunity: The role of molecular mimicry and immune crossreaction. Cell. Mol. Immunol. 2018 15 6 586 594 10.1038/cmi.2017.151 29503439
    [Google Scholar]
  29. Wraith D.C. Goldman M. Lambert P.H. Vaccination and autoimmune disease: What is the evidence? Lancet 2003 362 9396 1659 1666 10.1016/S0140‑6736(03)14802‑7 14630450
    [Google Scholar]
  30. Acosta-Ampudia Y. Anaya J.M. Reply to Cimolai: Post-COVID syndrome and autoimmunity. J. Infect. Dis. 2022 226 4 753 754 10.1093/infdis/jiac106 35313345
    [Google Scholar]
  31. Rojas M. Restrepo-Jiménez P. Monsalve D.M. Molecular mimicry and autoimmunity. J. Autoimmun. 2018 95 100 123 10.1016/j.jaut.2018.10.012 30509385
    [Google Scholar]
  32. Sogkas G. Atschekzei F. Adriawan I.R. Dubrowinskaja N. Witte T. Schmidt R.E. Cellular and molecular mechanisms breaking immune tolerance in inborn errors of immunity. Cell. Mol. Immunol. 2021 18 5 1122 1140 10.1038/s41423‑020‑00626‑z 33795850
    [Google Scholar]
  33. Hussein H.M. Rahal E.A. The role of viral infections in the development of autoimmune diseases. Crit. Rev. Microbiol. 2019 45 4 394 412 10.1080/1040841X.2019.1614904 31145640
    [Google Scholar]
  34. Smatti M.K. Cyprian F.S. Nasrallah G.K. Al Thani A.A. Almishal R.O. Yassine H.M. Viruses and autoimmunity: A review on the potential interaction and molecular mechanisms. Viruses 2019 11 8 762 10.3390/v11080762 31430946
    [Google Scholar]
  35. Getts D.R. Chastain E.M.L. Terry R.L. Miller S.D. Virus infection, antiviral immunity, and autoimmunity. Immunol. Rev. 2013 255 1 197 209 10.1111/imr.12091 23947356
    [Google Scholar]
  36. Rossi A. Magri F. Michelini S. New onset of alopecia areata in a patient with SARS‐CoV‐2 infection: Possible pathogenetic correlations? J. Cosmet. Dermatol. 2021 20 7 2004 2005 10.1111/jocd.14080 33738910
    [Google Scholar]
  37. Bertolotti A. Boniface K. Vergier B. Type I interferon signature in the initiation of the immune response in vitiligo. Pigment Cell Melanoma Res. 2014 27 3 398 407 10.1111/pcmr.12219 24438589
    [Google Scholar]
  38. Davitt E. Davitt C. Mazer M.B. Areti S.S. Hotchkiss R.S. Remy K.E. COVID-19 disease and immune dysregulation. Best Pract. Res. Clin. Haematol. 2022 35 3 101401 10.1016/j.beha.2022.101401 36494149
    [Google Scholar]
  39. Mazer M.B. Bulut Y. Brodsky N.N. Multisystem inflammatory syndrome in children: Host immunologic responses. Pediatr. Crit. Care Med. 2022 23 4 315 320 10.1097/PCC.0000000000002897 35050932
    [Google Scholar]
  40. Nyberg T. Ferguson N.M. Nash S.G. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: A cohort study. Lancet 2022 399 10332 1303 1312 10.1016/S0140‑6736(22)00462‑7 35305296
    [Google Scholar]
  41. Wolter N. Jassat W. Walaza S. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: A data linkage study. Lancet 2022 399 10323 437 446 10.1016/S0140‑6736(22)00017‑4 35065011
    [Google Scholar]
  42. Gupta L. Kharbanda R. Agarwal V. Misra D.P. Agarwal V. Patient perspectives on the effect of the SARS-CoV-2 pandemic on patients with systemic sclerosis. J. Clin. Rheumatol. 2021 27 1 31 33 10.1097/RHU.0000000000001681 33347032
    [Google Scholar]
  43. Sandhu N.K. Ravichandraan N. Nune A. Flares of autoimmune rheumatic disease following COVID ‐19 infection: Observations from the COVAD study. Int. J. Rheum. Dis. 2024 27 1 14961 10.1111/1756‑185X.14961 37969016
    [Google Scholar]
  44. Di Iorio M. Cook C.E. Vanni K.M.M. DMARD disruption, rheumatic disease flare, and prolonged COVID-19 symptom duration after acute COVID-19 among patients with rheumatic disease: A prospective study. Semin. Arthritis Rheum. 2022 55 152025 10.1016/j.semarthrit.2022.152025 35617780
    [Google Scholar]
  45. Redwan E.M. Alghamdi M.F. El-Aziz T.M.A. The mechanism behind flaring/triggering of autoimmunity disorders associated with COVID-19. Autoimmun. Rev. 2021 20 10 102909 10.1016/j.autrev.2021.102909 34274539
    [Google Scholar]
  46. Londe A.C. Fernandez-Ruiz R. Julio P.R. Appenzeller S. Niewold T.B. Type I interferons in autoimmunity: Implications in clinical phenotypes and treatment response. J. Rheumatol. 2023 50 9 1103 1113 10.3899/jrheum.2022‑0827 37399470
    [Google Scholar]
  47. Barzegar M. Vaheb S. Mirmosayyeb O. Afshari-Safavi A. Nehzat N. Shaygannejad V. Can coronavirus disease 2019 (COVID-19) trigger exacerbation of multiple sclerosis? A retrospective study. Mult. Scler. Relat. Disord. 2021 52 102947 10.1016/j.msard.2021.102947 33979771
    [Google Scholar]
  48. Zucchi D. Tani C. Elefante E. Impact of first wave of SARS-CoV-2 infection in patients with systemic lupus erythematosus: Weighting the risk of infection and flare. PLoS One 2021 16 1 0245274 10.1371/journal.pone.0245274 33439910
    [Google Scholar]
  49. Rojas M. Rodríguez Y. Acosta-Ampudia Y. Autoimmunity is a hallmark of post-COVID syndrome. J. Transl. Med. 2022 20 1 129 10.1186/s12967‑022‑03328‑4 35296346
    [Google Scholar]
  50. Liu Y. Ebinger J.E. Mostafa R. Paradoxical sex-specific patterns of autoantibody response to SARS-CoV-2 infection. J. Transl. Med. 2021 19 1 524 10.1186/s12967‑021‑03184‑8 34965855
    [Google Scholar]
  51. Camacho-Domínguez L. Rodríguez Y. Polo F. COVID-19 vaccine and autoimmunity. A new case of autoimmune hepatitis and review of the literature. J. Transl. Autoimmun. 2022 5 100140 10.1016/j.jtauto.2022.100140 35013724
    [Google Scholar]
  52. Ma W.T. Chang C. Gershwin M.E. Lian Z.X. Development of autoantibodies precedes clinical manifestations of autoimmune diseases: A comprehensive review. J. Autoimmun. 2017 83 95 112 10.1016/j.jaut.2017.07.003 28739356
    [Google Scholar]
/content/journals/crr/10.2174/0115733971382167250921213314
Loading
Risk of Autoimmune Rheumatic Diseases following COVID-19: A Systematic Review and Meta-Analysis
Bentham Science Publishers ; https://doi.org/10.2174/0115733971382167250921213314
/content/journals/crr/10.2174/0115733971382167250921213314
/content/journals/crr/10.2174/0115733971382167250921213314
Loading

Data & Media loading...

Supplements

PRISMA checklist is available as supplementary material on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Review Article
Keywords: COVID-19 ; autoimmunity ; behçet’s disease ; SARS-CoV-2 ; psoriasis ; dermatopolymyositis ; rheumatoid arthritis ; autoimmune diseases ; mixed connective tissue disease

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test